The Front Room — a clinical regulatory commons
RSS
← Back to The Docket
AUG 7 2026
APPROVED · 53 DAYS AGO

Moderna — mFLUSIVA (mRNA-1010) $MRNA

for Prevention of seasonal influenza

NDA

FDA approves Moderna's mRNA influenza vaccine mFLUSIVA for the prevention of seasonal influenza in adults.

About

Flu season is the yearly stretch of cold months when influenza outbreaks spread through a community, typically taking about two days after exposure for symptoms to appear and roughly three weeks to peak before fading. mFLUSIVA is an mRNA vaccine that delivers genetic instructions teaching the body's cells to make a piece of the influenza virus, so the immune system learns to recognize and attack it. Because that immune memory is built before exposure, the vaccine may help adults avoid getting sick when flu season arrives.

Pivotal trial

NCT05566639 Phase 3 completed NCT05566639

The purpose of this study is to evaluate the safety and efficacy of mRNA-1010 in preventing seasonal influenza in adults 50 years and older.

Source: ClinicalTrials.gov

Also in development